Antibody-based therapeutics have now had success in the clinic. The affinity and specificity of the antibody for the target ligand determines the specificity of therapeutic delivery and off-target side effects. The discovery and optimization of high-affinity antibodies to important therapeutic targets could be significantly improved by the availability of a robust, eukaryotic display technology comparable to phage display that would overcome the protein translation limitations of microorganisms. The use of eukaryotic cells would improve the diversity of the displayed antibodies that can be screened and optimized as well as more seamlessly transition into a large-scale mammalian expression system for clinical production. In this study, we demonstrate that the replication and polypeptide display characteristics of a eukaryotic retrovirus, avian leukosis virus (ALV), offers a robust, eukaryotic version of bacteriophage display. The binding affinity of a model single-chain Fv antibody was optimized by using ALV display, improving affinity >2,000-fold, from micromolar to picomolar levels. We believe ALV display provides an extension to antibody display on microorganisms and offers virus and cell display platforms in a eukaryotic expression system. ALV display should enable an improvement in the diversity of properly processed and functional antibody variants that can be screened and affinity-optimized to improve promising antibody candidates.
Antibody-based therapeutics have now had success in the clinic. The affinity and specificity of the antibody for the target ligand determines the specificity of therapeutic delivery and off-target side effects. The discovery and optimization of high-affinity antibodies to important therapeutic targets could be significantly improved by the availability of a robust, eukaryotic display technology comparable to phage display that would overcome the protein translation limitations of microorganisms. The use of eukaryotic cells would improve the diversity of the displayed antibodies that can be screened and optimized as well as more seamlessly transition into a large-scale mammalian expression system for clinical production. In this study, we demonstrate that the replication and polypeptide display characteristics of a eukaryotic retrovirus, avian leukosis virus (ALV), offers a robust, eukaryotic version of bacteriophage display. The binding affinity of a model single-chain Fv antibody was optimized by using ALV display, improving affinity >2,000-fold, from micromolar to picomolar levels. We believe ALV display provides an extension to antibody display on microorganisms and offers virus and cell display platforms in a eukaryotic expression system. ALV display should enable an improvement in the diversity of properly processed and functional antibody variants that can be screened and affinity-optimized to improve promising antibody candidates.
antibody engineering | avian leukosis virus | protein display technology | antibody binding affinity | avian leukosis virus polypeptide display A ntibodies have excellent target-binding specificities that have been exploited for the targeting of anticancer therapeutics specifically to tumor cells and the tumor microenvironment with success clinically (1) . Recent technological advances have begun to improve the tumor targeting capabilities of antibodies and antibody-linked therapeutics by engineering antibodies with modified properties: molecular size [Fabs, single-chain Fv antibodies (scFvs), and single-domain], antigen-binding affinity, specificity, and valency (1) (2) (3) . The optimal characteristics of particular antibodies and antibody fragments may vary considerably depending on the precise application. Therefore, technologies to efficiently optimize a lead antibody for a particular application are crucial for improving the efficacy of the therapeutic. As efficient rational design of antibodies is currently not feasible, the optimization of antibodies is best achieved by the randomization and subsequent selection of antibody mutants with the desired phenotypes by using polypeptide display technology.
Display technology refers to methods of generating libraries of modularly coded biomolecules displayed usually on microorganisms (bacteriophage, bacteria, yeast) and screening them for particular properties (4, 5) . The key feature of display technology is the linkage of a particular phenotype (displayed polypeptide) to its genotype (gene encoding the displayed polypeptide), enabling the rapid identification of the selected polypeptide(s). The most popular polypeptide display technology, phage display technology, has provided a versatile technology for the discovery and characterization of a variety of protein-protein interactions (6, 7) . However, bacteriophage display has significant limitations, mainly related to the restrictions imparted by Escherichia coli on the expression, assembly, folding, transport, and posttranslational modifications of the viral protein fusions and their incorporation into viral particles (8) . Finally, poor expression of the protein in eukaryotic cells can occur after selection using microorganism display platforms significantly delaying scale-up for therapeutic applications.
A robust, eukaryotic version of bacteriophage display would offer a solution to this technology bottleneck, enabling an improvement in the diversity of properly processed and functional antibody variants that can be screened and affinity-optimized to significantly improve promising antibody candidates compared with antibody display and affinity maturation using microorganisms. Recently, a mammalian cell surface antibody display system has offered one new approach, but this technology depends on the transient transfection of expression plasmids (9, 10) . A eukaryotic display technology that also has a virus display platform as well as cell surface display capabilities would be ideal. A display platform based on eukaryotic retroviruses could offer a solution: replicating in eukaryotic cells with an efficient quality control system that assesses whether a protein has been properly folded and modified, including retroviral glycoproteins, before transport to the cell surface and incorporation into virions (11, 12) . Previous published work demonstrated that the eukaryotic retrovirus MLV could function as a polypeptide display platform (13, 14) . However, since those initial studies, characteristics that significantly limit the usefulness of MLV as a display platform have been found: significant shedding of the displayed polypeptides, the fact that certain displayed polypeptides could block MLV infection, and the fact that a
Significance
There is a need for a robust and efficient eukaryotic polypeptide display platform for the discovery and affinity maturation of antibodies and other scaffolds, offering a powerful addition to the existing display technologies that use microorganisms. This study is significant in that it demonstrates just such a technology, avian leukosis virus (ALV) polypeptide display, supplying an innovative and substantive departure from the status quo of antibody display that uses platforms based on microorganisms. The use of eukaryotic cells provides the assurance of maximizing the proper folding, posttranslational modifications, and display of the single-chain Fv antibodies and the virus fusion proteins in virions and on the cell surface. ALV display offers virus and cell display platforms in a eukaryotic expression system. significant reduction in MLV infectivity occurred when displaying viral glycoprotein-polypeptide fusions (15, 16) .
We have previously demonstrated the initial feasibility of a display platform based on another eukaryotic retrovirus, the avian leukosis virus (ALV), with the ability to display a wide range of polypeptide sizes including scFvs as fusions with ALV envelope glycoproteins (17) , and with the ability to generate and screen a randomized uncensored peptide display library with >10 6 diversity (18) . This work demonstrated that the characteristics of ALV replication solved the severe limitations of polypeptide display using MLV, and provided a robust eukaryotic viral platform for the display of eukaryotic polypeptides as ALV surface (SU) glycoprotein fusions. The ability of the ALV genome to maintain at least 2.5 kb of additional sequence extends the possible sizes of the displayed polypeptides and/or offers space for an independent gene to encode a reporter protein or a second library of displayed polypeptides and still allow the RCAS series of replication-competent vectors to replicate to high titers in avian cells (19) .
In this study, we demonstrate that ALV display can be used to optimize ligand binding affinity as well as protein expression of a model scFv, providing a proof of principle that libraries of scFvs displayed as genetically stable ALV SU glycoprotein fusions offer a stable, soluble, relatively inert eukaryotic display platform for the display and selection of antibody libraries. Libraries of scFvs randomized at critical genomic sequence hotspots were generated and displayed as ALV SU glycoprotein fusions on virions, and then selected, improving the affinity of the model scFv more than 2,000-fold. The selection also significantly improved the expression level of the selected ALV SU-scFv fusion glycoproteins.
Results and Discussion
Efficient Delivery, Expression, and Display of scFvs Using a ReplicationCompetent Eukaryotic Virus in Eukaryotic Cells. Previously, we demonstrated that a wide variety of polypeptides fused to the ALV subgroup A envelope glycoprotein (ranging from an 8-aa peptide to a 244-aa scFv) could be delivered and expressed by using a replication-competent ALV vector that contains an additional reporter gene coding for alkaline phosphatase (AP) to simplify titer determination ( Fig. 1) (17, 18) . The scFv-Env(A) fusions have an N-terminal FLAG epitope tag, the scFv flanked by SfiI and NotI unique cloning sites, followed by the factor IX protease cleavage site and a flexible linker consisting of four glycines and a serine (G4S). Libraries of scFvs can be efficiently inserted into plasmids encoding the RCASBP vectors using unique SfiI and NotI cloning sites. By creating a virus with scFv-Env(A) fusions, FscFvXL(A), not only will the chicken DF-1 cells produce virions that display the mature scFv-Env(A) glycoprotein trimer, but the cells will display the same scFv-Env(A) fusion trimer, providing both a selection platform using virions and cells.
Two new display expression cassettes were constructed to facilitate the analysis of promising ligands/antibodies as a membrane-bound form of the polypeptide, pFscFv-M, and as a secreted form of the polypeptide, pFscFv-S (Fig. 1) . The polypeptide/scFv can be efficiently subcloned as a SfiI-NotI fragment into the unique SfiI-NotI sites of the expression cassettes. The flanking ClaI sites enable the subcloning of the scFv as an additional transgene into the unique ClaI site of a replicationcompetent RCAS vector like the envelope subgroup B RCASBP(B). Cells can then be generated that express the scFv as a membranebound protein (FscFv-M), or as a platform to express the scFv as a secreted protein (FscFv-S).
The RCAS vectors are simple to use to produce populations of cells in which all of the cells are infected and thereby produce virus stocks and express a foreign gene if desired (19, 20) . Plasmid DNA that contains a proviral copy of the RCAS vector is used to transfect chicken DF-1 cells in which the cells with plasmid DNA begin viral replication. As the viruses are replication-competent, the entire culture of cells becomes infected after splitting the cells several times. There is no exotic rescue or drug selection procedure needed. The supernatant from the infected cells contains the viral vector virions, creating the virus stock that can be further concentrated and stored frozen. If the RCAS vector contains an additional transgene, the transgene is expressed in all of the infected cells.
Construction, Expression, and Function of L36scFv-ALV Envelope
Glycoprotein Fusions Displayed on Virions. To demonstrate the feasibility of using ALV display for affinity-maturing a model scFv, the L36 scFv was used (21, 22) . L36 scFv recognizes a single, unique epitope on the ECM component laminin (900 kDa) that is thought to be exposed to scFv binding in the formation of tumor neovessels. Therefore, L36 scFv may provide the ability to target a variety of therapeutic molecules, including toxins and possibly oncolytic viruses, to the vulnerable tumor vasculature to combat tumor progression. Depending on the therapeutic to be targeted, a range of binding affinities of L36 scFv to laminin may be optimal. The binding affinity of the L36 scFv for laminin had not been previously reported to our knowledge. The L36 scFv gene was PCR-amplified to add flanking SfiI-NotI sites and then cloned into the SfiI-NotI sites of the FscFvXL(A)AP vector plasmid, the plasmid DNA Fig. 1 . Schematic representations of replication-competent ALV-based vectors that deliver and express genes encoding a scFv-envelope glycoprotein fusion, a secreted form of a scFv, or a membrane-bound form of an scFv. The standard RCASBP(A)AP vector contains the RCASBP gag, pol, and env genes, and the reporter gene, AP, flanked by LTRs. The FscFvXL(A) vector in addition to the RCASBP(A)AP sequences has an N-terminal fusion of a scFv fused to the N terminus of the subgroup A envelope glycoproteins. The scFvEnv(A) fusion protein consists of the signal peptide of Env(A) followed by the scFv cassette: the FLAG epitope tag, Sfi I site, the scFv gene, Not I site, and a flexible linker of four glycine and a serine residues (G4S), followed by the mature coding region of Env(A). Libraries of scFv domains are inserted by using the unique Sfi I and Not I sites. The ALV transcription splice donor (SD) and splice acceptor (SA) sites of the RCASBP vectors are shown. Two plasmid expression cassettes were constructed to facilitate the cloning of the same Sfi I and Not IscFv fragment to encode a secreted form of the scFv, pFscFv-S, or a membrane-bound form of the scFv, pFscFv-M. The FscFv-S expression cassette begins at a consensus Kozak translation start site (Nco I) followed by the signal peptide of the Tva receptor, the scFv coding region, a six-histidine (HIS6) epitope tag, all flanked by two Cla I sites. The FscFv-M cassette is the same as the scFv-S cassette but with the addition of the transmembrane and cytoplasmic region of the Tva receptor between the HIS6 tag and the Cla I site. These expression cassettes were subcloned by using the Cla I fragments inserted into the unique Cla I site of the transgene region of the subgroup B envelope glycoprotein ALV-based vector, RCASBP(B).
transfected into the chicken fibroblast cell line DF-1, and cells passaged to allow virus production and spread throughout the culture. The viral glycoproteins were analyzed by Western immunoblot and demonstrated that the L36scFv-Env(A) glycoprotein fusions were genetically stably maintained even after several passages (Fig. S1A , lane 4 vs. lanes 6 and 7) and migrated at a larger size compared with WT viral glycoproteins (Fig. S1A,  lanes 3, 4 ,6 , and 7 vs. lane 2). Virions displaying L36scFv specifically bound laminin-coated plates with more than a 1,000-fold enrichment compared with binding to another component of the ECM, fibronectin, and compared with a nonspecific scFv (Fig. S1B) .
We have previously established a robust FACS-based method for measuring the relative binding affinity of a variety of ALV viral glycoproteins expressed on the surface of infected cells for their ligands/receptors (23) . DF-1 cells infected with RCASBP(A)AP (Fig. S1C) expressing the WT envelope glycoprotein trimer on the cell surface, or cells infected with FL36scFvXL(A)AP (Fig. S1D) expressing the L36scFv-Env(A) glycoprotein trimers on the cell surface, were incubated with an anti-FLAG antibody FITC conjugate, and biotinylated laminin visualized after incubation with a NeutrAvidin-phycoerythrin (PE) conjugate. As expected, the cells expressing the WT ALV glycoproteins did not bind significantly to either probe (Fig. S1C) , whereas the cells expressing the L36scFv-Env(A) glycoprotein fusions bound anti-FLAG antibodies because of the FLAG epitope tag on the N terminus, and bound laminin as a result of the L36 scFv (Fig. S1D) . As can be seen in Fig. S1 , the ALV vector very efficiently delivers and expresses the L36scFv-viral glycoprotein to virtually all the cells in the culture. Variable expression levels on a cell-to-cell basis were expected because it is well known that the site of retroviral integration in the cell's genome can modulate the resulting protein expression level. To improve signalto-noise ratios in a FACS-based binding assay, the L36 scFvSfiI-NotI fragment was subcloned into the pFscFv-M expression cassette, and then the ClaI fragment subcloned into the RCASBP(B) vector. DF-1 cells infected with the RCASBP(B) vector alone (Fig. S1E) or with the RCASBP(B)-FL36scFv-M vector expressing the membrane-bound form of FL36scFv-M (Fig. S1F) were incubated with different concentrations of biotinylated laminin and the laminin binding quantitated with NeutrAvidin-PE and FACS analysis. The membrane-bound form of the L36scFv improved the signal to background laminin binding to where the binding affinity could be calculated (as detailed later). By using this FACS assay, we estimated that the L36 scFv has a binding affinity to biotinylated laminin of ∼2.2 nM.
Mapping the L36scFv Complementarity Determining Region (CDR)
Hotspots Responsible for Laminin Binding. A variety of approaches can be used to construct synthetic libraries of scFv variants to select for novel phenotypes including binding affinity. We used the approach of mimicking somatic hypermutation in vitro to improve antibody affinity (24) . The most studied consensus hotspots that may predict critical ligand binding residues are the tetranucleotide motif A/G-G-C/T-A/T and the serine codons A-G-C/T. The nucleotide sequence of L36scFv contained five of the tetranucleotide hotspots in CDR regions (Fig. S2) . The amino acid residues encoded by these hotspots are outlined in Fig. S3 . The hotspot amino acid residues were mutated to alanine in groups by CDR. For example, the two residues in immunoglobulin heavy chain variable region (VH), V H CDR1 hotspot, S31 and Y32, were both changed to alanine by site-directed mutagenesis, creating H1A (S31A+Y32A). The L36 scFv WT and mutants were cloned into the membranebound adapter plasmid and the ClaI fragments then subcloned into an RCASBP(B) vector. DF-1 cells were then transfected with the vector plasmids to begin virus production, and the cells passaged to allow virus spread to all cells. The protein expression levels of each membrane-bound scFv were normalized by measuring the levels of the FLAG epitope with anti-FLAG-FITC, and the fluorescence was quantified by using FACS (Fig. S4A) . In general, the expression levels of the different scFvs in cultures were remarkably consistent and required only very minor corrections likely because of the efficiency of scFv gene delivery and expression by the ALV-based vectors to all cells in the culture.
To determine the relative binding affinity of WT and mutant L36 scFvs for laminin, DF-1 cells expressing a nonspecific membrane-bound scFv (anti-CEA scFv) and DF-1 cells expressing the membrane-bound WT and mutant L36 scFvs were incubated with different concentrations of biotinylated laminin, followed by incubation with a NeutrAvidin-PE conjugate. The fluorescence from the bound complexes was quantified by using FACS and the results corrected for nonspecific binding of the biotinylated laminin and NeutrAvidin-PE by subtracting the level of fluorescence obtained from the anti-CEA scFv-expressing cells. The maximum mean fluorescence was estimated for each data set by fitting the data via a nonlinear least-squares method to a log logistic growth curve function described previously (23) . Only the mutations in the putative hotspots in V H CDR1 and V H CDR2 of L36 scFv reduced the binding affinity for biotinylated laminin by at least 1,000 fold, whereas the mutations in immunoglobulin light chain variable region (VL) V L CDR1 and V L CDR3 had no effect (Fig. S4B) . By using this assay, the estimated binding affinity of the WT L36 scFv was refined to 2.13 nM ( Table 1) . As the actual binding levels Table 1 . Analysis of L36 scFv CDR hotspots by alanine scanning mutagenesis
Round 1 data presented as average and SD of the data from three independent experiments. Round 2 data are results from a single experiment. measured for the mutant H1A and H2A scFvs were so low, only a gross estimate of the binding affinity was possible, in the micromolar range. Additional mutants were constructed with single mutations in the V H CDR1 and V H CDR2 hotspots and the binding affinity for biotinylated laminin was calculated. Two specific residues in the L36 scFv were critical for high-affinity binding of laminin: Y32 in V H CDR1 and V50 in V H CDR2.
Construction and Screening of an H1AscFv CDR Hotspot Randomized
Library for Improved Laminin Binding Affinity Variants. The mutant H1A32 scFv had an estimated binding affinity for biotinylated laminin in the micromolar range (Table 1 and Fig. S4B ). By using FH1A32scFvXL(A) as the template plasmid, a V H CDR1 randomized library of residues 31 and 32 was constructed by using three PCR reactions. Codons for residues S31 and Y32 in V H CDR1 were randomized in a PCR using oligonucleotides randomizing each codon using NNS (N can be A, C, G, or T; and S can be C or G) as the 3′-primer. The final PCR products were gel purified and digested with SfiI and NotI and gel purified and cloned into SfiI and NotI digested mutant L36 scFv Y32A FL36scFvXL(A)AP virus plasmid. A virus library displaying the scFvs with randomized V H CDR1 residues 31 and 32 was constructed as described previously (18) . Theoretically, only 1,024 unique clones are needed for the complete randomization of possible amino acid combinations when randomizing two residues for the V H CDR1 library (>1 × 10 4 actual plasmids picked). Deep nucleotide sequencing was performed on the V H CDR1 plasmid library to assess the actual randomization of the targeted 6 nt (Fig. S5) . The synthesized oligonucleotides used for the construction did not have exactly the expected distribution, especially in the third position of the second codon; however, all the possible amino acid pairs were represented in the library (Fig. S6) . A summary of the construction and screening of this library is provided in Table S1 .
To minimize possible avidity effects of the multiple copies of scFv-Env(A) fusion trimers on each virion (50-100), the selection for improved binding affinity was done in solution with biotinylated antigen, in this case biotinylated laminin ( Fig. 2A) . After incubation with the biotinylated laminin, NeutrAvidincoated beads were added to bind the biotinylated laminin. Virions bound to biotinylated laminin NeutrAvidin beads were extensively washed and then added to DF-1 cells in culture to amplify the captured viruses for several passages. The virus library of mutant L36scFv-Env(A) fusions randomized at V H CDR1 residues S31 and Y32 described earlier and in Table  S1 was first incubated with 2 nM biotinylated laminin, and the bound viruses were rescued and amplified, followed by three more rounds of selection with 1 nM, 0.5 nM, and 0.1 nM biotinylated laminin, respectively. Captured virus amplification was monitored by using an ELISA for the ALV CA protein and an ELISA for laminin binding to ensure the retention of the displayed scFv (Fig. 2B) . Approximately equal amounts of virions were analyzed by Western from the initial V H CDR1 library and from each selection/amplification round (Fig. 2C) . The displayed scFvs in the original library were maintained through four rounds of selection with little or no loss as shown by little or no WT viral glycoprotein observed in the Western immunoblot (Fig. 2C) . Significantly, the scFv-Env(A) mutants selected by round three express higher levels of the glycoprotein fusion per virion compared with earlier rounds. The selection procedure naturally selected mutants that express high levels of the scFvEnv(A) fusion glycoproteins.
Representative scFv regions from each round of selection were PCR-amplified from infected amplification cells and cloned, and the nucleotide sequences from 12 representative clones were determined and translated (Fig. 2D) . The scFv clones selected in the first two rounds of selection appeared to be random, but several representative clones already had a significantly improved affinity for laminin of <10 nM by the FACS binding assay (Table 2) . After the third round of selection, 2 of 12 clones encoded S31I, Y32F (IF), 2 of 12 clones encoded S31L, Y32F (LF), and 3 of 12 clones encoded S31N, Y32H (NH) that also contained an additional mutation in the framework outside the V H CDRs, I70V (NH+V70). After the fourth round, 11 of 12 clones encoded the NH+V70 changes. The relative binding affinities of the IF, LF, and NH+V70 scFvs had binding affinities of ∼2 nM: a >2,000-fold improvement in affinity compared with the starting H1A32 scFv.
A second pilot study was done, this time combining two separate randomized libraries: H1A as in the first study, and a library that randomized the 3 aa of the V H CDR2 using H2A as the template. The selection was done as in the first study. Two mutant scFvs were dominant after four rounds of selection: viruses with S31W+Y32S mutations in V H CDR1; or viruses with a S56V mutation in V H CDR2 but otherwise the WT V50 and N57 residues. Both these scFvs bound biotinylated laminin with affinities of ∼1 nM using the FACS binding assay ( Table 2 ). Note that the S31WY32S mutations in V H CDR1 were also selected in the first experiment (rounds 2 and 3) but did not remain the dominant clone after selection (Fig. 2D) . We constructed the combination of the S31WY32S mutations in V H CDR1 and the S56V mutation in V H CDR2 in the same scFv, which resulted in an improved binding affinity of ∼460 pM.
Binding Kinetics Using Surface Plasmon Resonance of Selected L36
Mutants Expressed as Secreted scFvs. To ensure that the scFvs selected as scFv-glycoprotein fusions would function as soluble scFvs, L36, several selected scFv mutants and a nonspecific scFv (anti-CEA scFv) were subcloned into pFscFv-S (Fig. 1) , expressed from chicken DF-1 cells or human amniocyte CAP-T cells, and purified by using the FLAG-epitope tag (Fig. S7) . We assayed the binding kinetics of these purified scFvs with immobilized laminin protein using surface plasmon resonance (SPR; Biacore; Table 2 ). Although the measured K d values using SPR were higher than estimated with the FACS binding assay, the overall levels of improvement from optimizing the H1A32 starting scFv ALV display were identical, with more than a 2000-fold improvement in binding affinity to laminin. Differences in the results may stem from the FACS binding assay using membranebound forms of the scFv on DF-1 cells to bind biotinylated laminin, while the SPR assay used unmodified laminin bound to the chip to then bind the purified scFvs.
Conclusions
In summary, these data demonstrate the feasibility and efficiency of using the ALV polypeptide display platform to affinity mature a scFv with an initial micromolar ligand binding affinity to <2 nM binding affinity, a >2,000-fold improvement. In addition, the natural characteristics of retroviruses produce a virus population containing quasispecies; virus members with a small number of mutations from errors during reverse transcription at a average rate of one error per 10 5 bases per cycle resulting mainly from the viral reverse transcriptase (25, 26) . As the FscFvXL(A)AP virus has a genome of ∼10 Kb, one error should arise in the genome of 1 in 10 viruses produced, so a stock of 10 6 viruses theoretically has a virus with one error at every position in the genome. In reality, the errors are distributed unevenly, but this exercise gives an indication of the incredibly high error rate of retroviruses, which, in combination with their propensity to recombine, offers a high level of additional diversity in any virus population including ALV display. These quasispecies provide additional mutants that can be selected if the n.c., not calculable. Data are presented as average and SD of the data from three independent experiments. *Constructed by mutagenesis. mutation provides an advantage under the experimental conditions. The dominant scFv selected from the V H CDR1 S31 Y32 randomization experiment not only encoded the S31N and Y32H mutations, but the I70V mutation in the framework of the scFv structure that most likely provided an additional advantage in laminin binding and/or protein expression. The I70V mutation most likely arose from the quasispecies in the virus library, although the I70V mutation with the S31L,Y32V mutations in one clone selected after round 1, not with the S31N,Y32H mutations selected starting in round 3 (Fig. S6) . Very few errors were observed outside the expected randomized residues 31and 32 (Fig. S5) .
Finally, the use of eukaryotic cells provides the assurance of maximizing the proper folding, posttranslational modifications, and display of the scFvs and the virus fusion proteins both in virions and on the cell surface. The use of a eukaryotic host may provide a smoother transition of the selected scFv to large-scale protein production for therapeutic applications. However, further optimization of a particular protein may be needed to optimize expression and/or posttranslational modifications in a production cell line, as there can be significant differences even between mammalian cell lines (27) . The RCAS vectors normally infect and replicate optimally in avian cells that express the appropriate receptors (19) . Mammalian cells do not express functional ALV receptors, but mammalian cell lines and transgenic mice have been engineered to express ALV receptors and thereby conferring susceptibility to ALV infection. Although RCAS vectors can then infect the mammalian cells expressing the appropriate receptor, and integrate into the cells genome delivering and expressing a transgene, there are multiple blocks to new virus formation. RCAS-based viruses have also been designed to infect mammalian cells efficiently using the amphotropic MLV envelope glycoprotein, RCASBP-M2C(797-8), and deliver and express transgenes, but again are blocked from the production of new viruses (28) . In future experiments, the RCASBP-M2C(797-8) virus will be tested for delivering and expressing membranebound scFv libraries in CHO and HEK293 mammalian cell lines, often used for large-scale protein production by infection and then cell surface selection using FACS.
Methods
The RCAS vector system has been reviewed previously (19, 20) . The RCASBP(A) AP with the heat-stable human placental AP gene and the FscFvXL(A)AP vector with the FLAG-SfiI-NotI-Fxa-G4S linker fused to the subgroup A envelope glycoprotein have also been previously described (17) . The L36 scFv (22) was subcloned as a SfiI-NotI fragment into the SfiI and NotI sites of FXL (A)AP to create the replication-competent FL36scFvXL(A)AP viral vector. ALVs were propagated by using DF-1 cells, a chicken fibroblast cell line as described previously (29) . Viral spread was monitored by assaying culture supernatants for ALV capsid protein (CA) by ELISA. Virus stocks were generated from cell culture supernatants, and virus titers determined by mixing 10-fold serial dilutions of the virus stock with DF-1 cells and assaying for APpositive infectious units (ifus) 48 h later as described previously (23) . DF-1 cells expressing membrane-bound scFvs (∼1 × 10 6 ) and biotinylated laminin were used to estimate laminin-binding affinities by using a FACS-based assay. Selected L36 scFv mutants were expressed as secreted FLAG-tagged scFvs purified using FLAG-affinity resin, and binding affinities measured using SPR. L36 scFv V H CDR1 hotspot residues S31 and Y32 were randomized by using three PCR reactions using the mutant L36 scFv Y32A FL36scFv(A) virus plasmid. The plasmid library, the initial virus library, and the deconvoluted virus library were generated as described previously (18) and screened as summarized in Table S1 . The concentrated deconvoluted virus library was incubated with the appropriate concentration of biotinylated laminin and washed, and the viruses bound to biotinylated laminin were collected by incubation with the blocked NeutrAvidin agarose resin, and then the resin was collected by centrifugation. The resin-virus laminin complexes were washed and then added to DF-1 cell cultures to rescue and amplify the bound viruses. Additional method details are provided in SI Methods. 
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